Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;59(2):195-204.
doi: 10.11406/rinketsu.59.195.

[Mesenchymal Stem Cell Therapy in Hematopoietic Stem Cell Transplantation]

[Article in Japanese]
Affiliations
Review

[Mesenchymal Stem Cell Therapy in Hematopoietic Stem Cell Transplantation]

[Article in Japanese]
Tatsunori Goto et al. Rinsho Ketsueki. .

Abstract

Mesenchymal stem cells (MSCs) have received considerable attention in allogeneic hematopoietic cell transplantation because of their abilities to modulate immune responses and promote hematopoiesis. Because MSCs are capable of producing several cytokines and growth factors, they have been widely used in the treatment of graft-versus-host disease (GVHD). A number of clinical trials have demonstrated the safety and efficacy of MSC therapy for acute GVHD. Moreover, in Japan, allogeneic bone marrow-derived MSC product, TEMCELL®, was approved as a regenerative medicine for acute GVHD. Besides, MSCs can also produce bone marrow stroma and promote hematopoiesis, the co-transplantation of hematopoietic stem cells and MSCs have been efficiently performed in cord blood transplantation and HLA-mismatched transplantation to enhance engraftment and prevent GVHD. In this review, we provide an overview of clinical trials using MSCs in allogeneic hematopoietic cell transplantation and discuss the possibilities and optimization of MSC therapy.

Keywords: Engraftment; Graft-versus-host disease; Hematopoietic stem cell transplantation; Mesenchymal stem cell.

Similar articles

See all similar articles

MeSH terms

Feedback